SAR447537

Phase 2Small molecule

Sanofi

SAR447537 is one of 9 small molecule programs targeting Alpha-1 Antitrypsin Deficiency. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alpha-1 Antitrypsin DeficiencyRecruiting

Alpha-1 Antitrypsin DeficiencyPhase 2

Recruiting

Competition

Competitive Landscape

15 competitors in Alpha-1 Antitrypsin Deficiency

#DrugCompanyPhaseTrials

Zofran

Novartis

Preclinical

1 2

Duragesic

CCephalon

Preclinical

1 3

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 4

Tylenol

KKenvue Brands

Preclinical

1 5

Ativan

BBausch Health Americas, Inc.

Preclinical

1 6

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 7

SAR447537

Sanofi

Phase 2

1 8

WVE-006

WWave Life Sciences Ltd.

Preclinical

1 9

Oxycodone/acetaminophen

MMontefiore Medical Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Recruiting

Alpha-1 Antitrypsin Deficiency

NCT05897424

Clinical

Trials by Indication[1]

Alpha-1 Antitrypsin Deficiency1 trial

Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema

Recruiting· Sanofi logo

Sanofi·Phase 2·NCT05897424·185 enrolled

Emphysema1 trial

Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema

Completed· Sanofi logo

Sanofi·Phase 2·NCT05856331·99 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for SAR447537. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SAR447537 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SAR447537. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Sanofi

SAR447537

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Alpha-1 Antitrypsin Deficiency1 trial

Emphysema1 trial

References

Drug Info

Quick Facts

Related News